4-benzyloxy-2-fluoro-benzyl bromide | 504414-34-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-benzyloxy-2-fluoro-benzyl bromide
• 英文别名: 4-benzyloxy-1-bromomethyl-2-fluoro-benzene；4-(Benzyloxy)-1-(bromomethyl)-2-fluorobenzene；1-(bromomethyl)-2-fluoro-4-phenylmethoxybenzene
• CAS: 504414-34-0
• 化学式: C₁₄H₁₂BrFO
• 分子量: 295.151
• InChiKey: QWKSWSFBXNUZPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-benzyloxy-2-fluoro-benzyl bromide 在 氢氧化钾 作用下， 以 乙醇 、 水 为溶剂， 以81%的产率得到4-benzyloxy-2-fluoro-phenyl acetic acid
  参考文献：
  名称：

  Compositions and methods using compounds having cytochrome P450RAI inhibitory activity co-administered with vitamin A

  摘要：

  维生素A，或具有维生素A活性的维生素A衍生物与CP450RAI1和/或CP450RAI2酶的抑制剂共同给药，用于治疗哺乳动物，包括人类的疾病和状况，这些疾病或状况可以通过施用视黄酸化合物或通过哺乳动物机体自然存在的视黄酸来预防、治疗、改善或延迟其发作。

  公开号：

  US20040077721A1
• 作为产物：
  描述：

  [4-(benzyloxy)-2-fluorophenyl]methanol 在 吡啶 、 phosphorus tribromide 作用下， 以 乙醚 为溶剂， 生成 4-benzyloxy-2-fluoro-benzyl bromide
  参考文献：
  名称：

  Compositions and methods using compounds having cytochrome P450RAI inhibitory activity co-administered with vitamin A

  摘要：

  维生素A，或具有维生素A活性的维生素A衍生物与CP450RAI1和/或CP450RAI2酶的抑制剂共同给药，用于治疗哺乳动物，包括人类的疾病和状况，这些疾病或状况可以通过施用视黄酸化合物或通过哺乳动物机体自然存在的视黄酸来预防、治疗、改善或延迟其发作。

  公开号：

  US20040077721A1

文献信息

• 4-[(8-Ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome P450RAI inhibitory activity
  申请人：——

  公开号：US20030191181A1

  公开（公告）日：2003-10-09

  Compounds of Formula 1 1 wherein the variables are defined in the specification have cytochrome P450RAI-1 and P450RAI-2 inhibitory activity, and are suitable for treatment of mammals with conditions which are treatable with retinoids, or which are controlled by or responsive to the organism's native retinoic acid. Formulations containing the compounds of the invention can also be co-administered with retinoids and/or Vitamin A to enhance or prolong the effects of medications containing retinoids, Vitamin A, or of the organism's native retinoic acid.

  公式1的化合物 1 其中，变量在说明书中定义，具有细胞色素P450RAI-1和P450RAI-2的抑制活性，适用于治疗可用视黄酸治疗的哺乳动物疾病，或由生物体的天然视黄酸控制或响应的疾病。包含本发明的化合物的制剂还可以与视黄酸和/或维生素A共同给药，以增强或延长含有视黄酸、维生素A或生物体天然视黄酸的药物的效果。
• 4-[(8-Substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-yl-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity
  申请人：——

  公开号：US20030207937A1

  公开（公告）日：2003-11-06

  Compounds of the formula 1 where the variables are defined in the specification have cytochrome P450RAI-1 and P450RAI-2 inhibitory activity, and are suitable for treatment of mammals with conditions which are treatable with retinoids, or which are controlled by or responsive to the organism's native retinoic acid. Formulations containing the compounds of the invention can also be co-administered with retinoids and/or Vitamin A to enhance or prolong the effects of medications containing retinoids, Vitamin A, or of the organism's native retinoic acid.

  具有公式1的化合物，其中变量在说明书中定义，具有细胞色素P450RAI-1和P450RAI-2的抑制活性，并且适用于治疗可通过视黄酸治疗的哺乳动物疾病，或由生物体的天然视黄酸控制或响应的疾病。包含本发明的化合物的制剂还可以与视黄酸和/或维生素A共同给药，以增强或延长含有视黄酸、维生素A或生物体天然视黄酸的药物的效果。
• Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives
  申请人：Himmelsbach Frank

  公开号：US20070072813A1

  公开（公告）日：2007-03-29

  The invention relates to methods for preventing or treating metabolic disorders, for improving glycemic control, for preventing progression from impaired glucose tolerance, insulin resistance and/or from metabolic syndrome to type 2 diabetes mellitus, for preventing or treating of complications of diabetes mellitus, for reducing the weight, for preventing or treating the degeneration of pancreatic beta cells, for treating hyperinsulinemia and insulin resistance and diabetes type 1, in patients in need thereof by administering a pharmaceutical composition comprising a pyrazole-O-glycoside as defined in claim 1, or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

  本发明涉及一种预防或治疗代谢性疾病的方法，改善血糖控制，预防从糖耐量受损、胰岛素抵抗和/或代谢综合征进展到2型糖尿病，预防或治疗糖尿病并发症，减轻体重，预防或治疗胰岛β细胞退化，治疗高胰岛素血症和胰岛素抵抗以及1型糖尿病，方法是通过给需要的患者口服含有在权利要求1中定义的吡唑烷-O-糖苷或其前药或其药学上可接受的盐的药物组成物。
• 4-[(8-ETHYNYL, 8-VINYL OR 8-ETHYNYL-METHYL)-6-CHROMANOYL]-BENZOIC AND 2-[4-[(8-ETHYNYL, 8-VINYL OR 8-ETHYNYL-METHYL)-6-CHROMANOYL]-PHENYL]-ACETIC ACID, THEIR ESTERS AND SALTS HAVING CYTOCHROME P450RAI INHIBITORY ACTIVITY
  申请人：Allergan, Inc.

  公开号：US06740676B2

  公开（公告）日：2004-05-25

  Compounds of Formula 1: wherein the variables are defined in the specification have cytochrome P450RAI-1 and P450RAI-2 inhibitory activity, and are suitable for treatment of mammals with conditions which are treatable with retinoids, or which are controlled by or responsive to the organism's native retinoic acid. Formulations containing the compounds of the invention can also be co-administered with retinoids and/or Vitamin A to enhance or prolong the effects of medications containing retinoids, Vitamin A, or of the organism's native retinoic acid.

  式1的化合物：其中变量在规范中定义，具有细胞色素P450RAI-1和P450RAI-2的抑制活性，并适用于治疗哺乳动物的疾病，这些疾病可用视黄醇治疗，或受到或响应于生物体的本地视黄酸的控制。含有本发明化合物的制剂也可以与视黄醇和/或维生素A一起共同使用，以增强或延长含有视黄醇、维生素A或生物体本地视黄酸的药物的效果。
• 4-[(8-substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-YL-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity
  申请人：Allergan, Inc.

  公开号：US07351737B2

  公开（公告）日：2008-04-01

  Compounds of the formula where the variables are defined in the specification have cytochrome P450RAI-1 and P450RAI-2 inhibitory activity, and are suitable for treatment of mammals with conditions which are treatable with retinoids, or which are controlled by or responsive to the organism's native retinoic acid. Formulations containing the compounds of the invention can also be co-administered with retinoids and/or Vitamin A to enhance or prolong the effects of medications containing retinoids, Vitamin A, or of the organism's native retinoic acid.

  式中变量的化合物具有细胞色素P450RAI-1和P450RAI-2的抑制活性，并适用于治疗哺乳动物的疾病，这些疾病可用维甲酸治疗，或者受到机体本身的视黄酸的控制或反应。含有本发明化合物的制剂也可以与维甲酸和/或维生素A共同使用，以增强或延长含有维甲酸、维生素A或机体本身的视黄酸的药物的效果。